[PDF][PDF] MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed …
Journal of Clinical Oncology, 2008•academia.edu
Purpose Standard therapy for glioblastoma (GBM) is temozolomide (TMZ) administration,
initially concurrent with radiotherapy (RT), and subsequently as maintenance therapy. The
radiologic images obtained in this setting can be difficult to interpret since they may show
radiation-induced pseudoprogression (psPD) rather than disease progression.
initially concurrent with radiotherapy (RT), and subsequently as maintenance therapy. The
radiologic images obtained in this setting can be difficult to interpret since they may show
radiation-induced pseudoprogression (psPD) rather than disease progression.
Purpose
Standard therapy for glioblastoma (GBM) is temozolomide (TMZ) administration, initially concurrent with radiotherapy (RT), and subsequently as maintenance therapy. The radiologic images obtained in this setting can be difficult to interpret since they may show radiation-induced pseudoprogression (psPD) rather than disease progression.
academia.edu